Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/082,542external-prioritypatent/US7059520B1/en
Application filed by Wyeth CorpfiledCriticalWyeth Corp
Publication of AR048275A1publicationCriticalpatent/AR048275A1/en
Composiciones farmacéuticas y métodos para su dosificacion. Reivindicacion 1 : un compuesto que es 4-ciano-N-{(2R)-2[4-(2,3-dihidro-benzo[1,4]dioxin-5-il)-piperazin-1-il]-propil}-N-piridin-2-il-benzamida o una sal farmacéuticamente aceptable de la misma en forma de partículas con un diámetro medio de no más de aproximadamente 20micras.Pharmaceutical compositions and methods for dosing. Claim 1: a compound that is 4-cyano-N - {(2R) -2 [4- (2,3-dihydro-benzo [1,4] dioxin-5-yl) -piperazin-1-yl] -propyl } -N-Pyridin-2-yl-benzamide or a pharmaceutically acceptable salt thereof in the form of particles with an average diameter of no more than about 20 microns.
ARP0501010582004-03-192005-03-18
4-CIANO-N - {(2R) -2 [4- (2,3-DIHIDRO-BENZO [1,4] DIOXIN-5-IL) -PIPERAZIN-1-IL] -PROPIL} -N-PIRIDIN-2 -IL-BENZAMIDA, DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS
AR048275A1
(en)
Use of (s) -n- (2- (1,6,8-tetrahydro-2h-inden [5,4-b] furan-8-yl) ethyl] propionamide in combination with one or more drugs selected from a group defined to prepare a drug useful for the prevention or treatment of depression or anxiety disorders (divisional application 749-2006).